Contineum Therapeutics

CTNMPhase 2

Contineum Therapeutics leverages its expertise in neuro-immunology to develop next-generation therapies for complex diseases of the central nervous system and inflammatory conditions. The company's strategy centers on targeting specific receptor pathways implicated in disease progression, with its lead candidate, PIPE-307, in Phase 2 for multiple sclerosis and PIPE-791 in Phase 1 for idiopathic pulmonary fibrosis. Following its successful IPO in April 2024, Contineum is well-capitalized to advance its clinical pipeline and explore the therapeutic potential of its novel mechanisms of action.

Market Cap

$398.9M

Employees

11-50

Focus

Biotech

CTNM · Stock Price

USD 12.213.19 (-20.71%)

Historical price data

AI Company Overview

Technology Platform

Focused drug discovery on specific receptor pathways, particularly the lysophosphatidic acid 1 (LPA1) receptor and the muscarinic M1 receptor, to develop oral, brain-penetrant small molecule therapies for neuroinflammatory and fibrotic diseases.

Pipeline Snapshot

8 drugs in pipeline

Drug	Indication	Stage
PIPE-791 Dose A + PIPE-791 Dose B + Placebo	Idiopathic Pulmonary Fibrosis	Phase 2
PIPE-307 Dose A + PIPE-307 Dose B + Placebo	Relapsing Remitting Multiple Sclerosis	Phase 2
PIPE-505 + Placebo	Sensorineural Hearing Loss	Phase 1/2
PIPE-791	Idiopathic Pulmonary Fibrosis (IPF)	Phase 1
PIPE-307	Multiple Sclerosis	Phase 1

Funding History

Total raised: $190M

Series B$110MBristol Myers SquibbApr 15, 2023

Series A$80MPfizerJan 15, 2022

Opportunities

Contineum's primary growth opportunities lie in successfully demonstrating clinical proof-of-concept for its novel mechanisms in large markets like multiple sclerosis and idiopathic pulmonary fibrosis.

Positive data could unlock significant partnership potential with larger pharma and expand into adjacent fibrotic and neuroinflammatory indications for its LPA1 and M1 receptor platforms.

Risk Factors

Key risks include clinical trial failure for its lead assets, intense competition from established therapies in its target markets, the challenge of proving remyelination in humans, and dependence on future financing to reach commercialization.

The novel mechanisms, while promising, are unproven in late-stage studies.

Competitive Landscape

Contineum faces competition from established MS immunomodulators (e.g., Roche, Biogen) and IPF anti-fibrotics (e.g., Genentech, Boehringer Ingelheim). Its differentiation strategy is based on novel mechanisms (M1 modulation for remyelination, brain-penetrant LPA1 inhibition) that address unmet needs beyond current standards of care, targeting disease modification rather than just symptom management.

Publications

Patents

Pipeline